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A B S T R A C T
Idiopathic achalasia and Barrett's esophagus (BE) are preneoplastic conditions of the esophagus. BE increases the risk of esophageal adenocarcinoma (EAC), while
achalasia is associated with both EAC and esophageal squamous cell carcinoma (ESCC). However, while the molecular mechanisms underlying the transformation of
esophageal epithelial cells in BE are relatively well characterized, less is known regarding these processes in achalasia. Nevertheless, both conditions are associated
with chronic inﬂammation and BE can occur in achalasia patients, and it is likely that similar processes underlie cancer risk in both diseases. The present review will
discuss possible lessons that we can learn from the molecular analysis of BE for the study of achalasia-associated cancer and contrast ﬁndings in BE with those in
achalasia. First, we will describe cellular fate during development of BE, EAC, and ESCC, and consider the inﬂammatory status of the epithelial barrier in BE and
achalasia in terms of its contribution to carcinogenesis. Next, we will summarize current data on genetic alterations and molecular pathways involved in these
processes. Lastly, the plausible role of the microbiota in achalasia-associated carcinogenesis and its contribution to abnormal lower esophageal sphincter (LES)
functioning, the maintenance of chronic inﬂammatory status and inﬂuence on the esophageal mucosa through carcinogenic by-products, will be discussed.
1. Introduction
Achalasia is an uncommon motility disorder of the esophagus
characterized by impaired esophageal peristalsis and reduced lower
esophageal sphincter (LES) relaxation [1]. The impeded ﬂow of in-
gested food and secretions from the esophagus into the stomach leads to
clinical symptoms as dysphagia, regurgitation of undigested food,
weight loss and chest pain [2]. Current evidence suggests that an initial
inﬂammation in the myenteric plexus, most likely caused by a viral
disease or other environmental factors, leads to an autoimmune re-
sponse in genetically susceptible individuals. This results in a degen-
eration of the myenteric ganglion neurons that control esophageal
motility [1].
As achalasia is a disorder with poorly studied etiology, available
treatments aim to alleviate symptoms by diminishing the LES pressure
[1]. This can be achieved by endoscopic botulin toxin injection, surgical
myotomy with or without a fundoplication, pneumatic dilatation or
per-oral endoscopic myotomy (POEM) as a new minimally invasive
treatment [3,4]. However, eﬀective treatment of achalasia may prompt
signiﬁcant sphincter insuﬃciency, resulting in gastro-esophageal reﬂux
disease (GERD) and its complications such as chronic inﬂammation of
the esophagus (esophagitis) and Barret's esophagus (BE) [5]. BE is
characterized by the replacement of normal squamous epithelium of the
lower esophagus with metaplastic columnar epithelium. This
transformation is called intestinal metaplasia, and poses a risk factor for
the development of esophageal adenocarcinoma (EAC). The annual
EAC incidence rate in BE cohorts varies from 0.12 to 3.55% in diﬀerent
studies [6] while the global EAC incidence rate is 0.7 per 100,000 but
varies greatly across countries [7]. Treatment of achalasia is associated
with an increased EAC risk, with an incidence of 21.23 (StDev31.6)
cases per 100,000 patient-years at risk compared to 3.2 cases/100,000
patient-years in the general population in this study [8]. Prevalence for
EAC in achalasia patients is 6 per 1000 after endoscopic cardia dilata-
tion, and 7 cases per 1000 achalasia patients after myotomy in studies
exclusively evaluating results after endoscopic cardia dilatation and
myotomy respectively [8]. Fundoplication after laparoscopic myotomy
decreases the incidence of postoperative GERD by preventing acid re-
ﬂux into the esophagus [3].
On the other hand, in suboptimal treated or non-treated achalasia
patients, bacterial overgrowth and chemical irritation from the ongoing
decomposition of food and saliva can also lead to chronic hyperplastic
esophagitis and malignant transformation of esophageal epithelial cells
to esophageal squamous cell carcinoma (ESCC) [9]. A recent review and
meta-analysis determined the risk of ESCC in achalasia patients to be
312.4 (StDev 429.16) cases per 100,000 patient-years at risk, compared
to 4.3 cases/100,000 patient-years in the general population in this
study [8]. Worldwide, ESCC accounts for around 90% of the 456,000
cases of esophageal cancers seen each year, with a global incidence rate
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of 5.2 per 100,000 [7].
Also ESCC in BE patients can occur, although very rare [10]. Thus,
development of esophageal cancer in achalasia patients may occur via
two independent pathways: direct transformation of squamous epithe-
lium to ESCC or to EAC after BE development.
Despite the fact that achalasia is associated with an increased risk of
two diﬀerent types of esophageal cancer, there are no generally ac-
cepted recommendations on follow-up evaluation for achalasia patients
[11]. This may be explained by the fact that although the gastro-eso-
phageal cancer risk in patients with longstanding achalasia is much
higher than in the general population, the absolute risk is relatively low
[12,13] as idiopathic achalasia is a relatively rare disease with a mean
incidence of 0.3–1.63 per 100,000 people per year in adults. Never-
theless, the majority of patients with esophageal carcinoma have a poor
prognosis as they are often diagnosed at advanced stages, no longer
eligible for curative surgery. Delay in the diagnosis of esophageal car-
cinoma is related to diﬃculties in endoscopic surveillance of achalasia
due to stasis of food and because the main symptoms of esophageal
carcinoma are mistakenly attributed to achalasia. Therefore, approxi-
mately 80% of patients are inoperable at initial diagnosis [14].
Radiotherapy, chemotherapy or chemoradiotherapy in both EAC and
ESCC are less eﬃcient resulting in a 5-year survival rate of 19% for
esophageal cancer and only 0.9% for advanced esophageal cancer [15].
A better insight into the molecular pathways governing esophageal
cancer development in achalasia and BE may be of use to identify pa-
tients at risk, better inform patients on associated neoplastic progres-
sion risk after dilatation treatment aiming to improve surveillance and
treatment strategies.
While the possible mechanisms determining the progression of BE to
EAC are relatively well studied, EAC or ESCC in the context of achalasia
are relatively underinvestigated. However, taking into account that
both disorders are associated with chronic inﬂammation of the eso-
phagus and development of BE in achalasia patients has been described
[16], it is likely that similar molecular mechanisms contribute to cancer
development. This review will consider possible lessons that can be
learned from the molecular analysis of BE-associated adenocarcinoma
for studying achalasia-associated cancer development and describe the
probable role of chronic esophagitis, gene mutations and molecular
pathways alterations and microbiota changes involved in the malignant
transformation.
1.1. Cellular fate in BE, EAC and ESSC
The normal esophageal mucosa consists of a nonkeratinizing, stra-
tiﬁed squamous epithelium, lamina propria, and muscularis mucosae
[17]. Gastroesophageal reﬂux is a normal physiological process in
Fig. 1. Cells of origin of Barrett's esophagus (BE), esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) in achalasia patients (extended
from Jiang et al. 2017 [111]. I. The esophageal epithelium of achalasia patients is diﬀerent from normal squamous epithelium: it is inﬂamed, has dilated intercellular
spaces and increased inﬁltration of inﬂammatory cell [38]. II. Treatment of achalasia can lead to gastro-esophageal reﬂux disease (GERD) and BE (III). Several
hypotheses are suggested to explain cells of origin of BE: a) BE epithelium arises through transdiﬀerentiation of stratiﬁed squamous esophageal epithelium; b)
circulating bone marrow cells transdiﬀerentiate to BE epithelium; c) BE arises from expanded esophageal submucosal gland cells; d) BE originates from stem and
progenitor cells (Lgr5+) in the cardia mucosa; e) BE originates from quiescent residual embryonic cells (REC) at the squamous-columnar junction. IV. BE can lead to
EAC wich originates from glandular cells near the stomach (0.02% of achalasia patients/year). Sporadically, ESCC can develop from BE (not shown). V. ESCC is
derived from squamous epithelial cells (0.31% of achalasia patients /year).
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humans, occurring after a meal. In addition to gastric acid, the reﬂuxate
contains pepsin, bile, pancreatic enzymes, ingested foods and their
metabolites [18]. Anti-reﬂux and tissue resistance mechanisms are in
place to protect the esophageal mucosa against these abrasive ﬂuids
[19].
However, these physiological defense mechanisms may no longer be
suﬃcient when poor closure of the LES occurs and a subsequently in-
creased frequency of gastroesophageal reﬂux causes GERD [19]. Eso-
phageal epithelial barrier function is disrupted in GERD, with decreased
expression of tight junction proteins resulting in increased barrier
permeability compared with healthy subjects [20]. GERD, itself char-
acterized by squamous hyperplasia, elevated presence of intraepithelial
inﬂammatory inﬁltrate, epithelial cell necrosis and lack of surface
maturation, is a precursor to BE. The metaplastic columnar epithelium
of BE appears to be more resistant to reﬂux-induced injury than the
native squamous cells [21] making it tempting to speculate that se-
lection pressure contributes to the development of BE. It is composed of
mucinous columnar epithelial cells arranged in surface and crypt epi-
thelia, and contains a variable number of scattered goblet cells, en-
terocytes, Paneth cells, endocrine cells, and cells with combined gas-
tric/intestinal or intestinal/squamous-cell features [22].
There is a lot of debate regarding the cell of origin of BE. So far, six
hypotheses have been suggested [23]: 1) transdiﬀerentiation of eso-
phageal squamous epithelial cells, 2) expansion of submucosal gland-
ular epithelium, 3) expansion of gastric cardia cells, 4) diﬀerentiation of
circulating bone marrow cells, 5) expansion of residual embryonic cells
located at the squamous-columnar junction, 6) p63+KRT5+KRT7+
basal cells in a transitional zone between the epithelium of the eso-
phagus and cardia (Fig. 1).
The suggestion is made that whatever the cell of origin, this is also
the origin of the subsequent progression to EAC. However, while it is
clear that EAC originates from glandular cells near the stomach, BE
consists of many cell types, and thus it remains uncertain which cells
are the main drivers of EAC. In contrast, ESCC is derived from squa-
mous epithelial cells and appears to be driven by carcinogenic en-
vironmental inﬂuences, but may also go through dysplastic precursor
lesions (Fig. 1) [24]. Cell types present in the esophageal mucosa in
described esophageal disorders are summarized in Table 1.
2. The possible role of chronic inﬂammation in the progression of
BE and achalasia toward esophageal cancer
2.1. Inﬂammation and BE
Chronic inﬂammation is associated with an increased risk of ma-
lignant disease. Around 20% of human cancers are related to chronic
inﬂammation caused by infections, exposure to irritants or autoimmune
disease [25]. Inﬂammation may contribute to cancer development
through numerous mechanisms, including DNA damage, angiogenesis,
promotion of cellular proliferation, and inhibition of apoptosis [26].
Indeed, inﬂammatory conditions of the esophagus, speciﬁcally reﬂux
esophagitis and BE, have been implicated in the development of eso-
phageal adenocarcinoma [27]. Metaplasia can be accompanied by
acute and chronic inﬂammation of the lower esophagus resulting in
increased release of proinﬂammatory mediators [28]. Key mediators
connecting inﬂammation and BE carcinogenesis include ROS, NFκB
pathway activation, inﬂammatory cytokines, prostaglandins, and im-
mune modulatory microRNAs [28]. For instance, IL-1β, a pleiotropic
pro-inﬂammatory cytokine upstream of inﬂammatory IL-6 and TNF-α
signaling cascades, is overexpressed in BE. Clinical studies have sug-
gested that polymorphisms in the IL-1β gene cluster are associated with
BE, suggesting that genetic factors predisposing for altered immune
regulation contribute to BE susceptibility [29]. In addition, inﬂamma-
tion markers, particularly C-reactive protein and IL-6, were proposed as
potential markers for patients with a higher risk of progression to EAC
[30]. Furthermore, expression of TNF-α as well as its receptor TNF-R1
are progressively increased from normal squamous mucosa to BE and
EAC [31]. The inﬂammatory link with esophageal adenocarcinoma is
further strengthened by the observation that regular use of nonsteroidal
anti-inﬂammatory drugs and aspirin is correlated with decreased risk of
cancer development [32].
2.2. Inﬂammation and achalasia
To what extent inﬂammation plays a role in achalasia and its pro-
gression to ESCC or BE-EAC is less clear. Systemic inﬂammation has
been shown in achalasia patients as compared to healthy controls [33],
and corresponded with increased Th17 and Th2 (INF-γ) cytokine levels
and decreased Th1 levels [34], although these ﬁndings were not sub-
stantiated in another study [35]. Achalasia is in itself thought to be an
auto-immune condition, in which the mesenteric plexus neurons and
ganglions are surrounded by inﬁltrating CD8+ cytotoxic T-cells, eosi-
nophils, B-cells and mast cells and anti-neuronal antibodies are being
produced [36]. However, diﬀerent subtypes of achalasia may be dis-
tinguished, with type I devoid of esophageal motility and minimal
pressurization, type II showing a simultaneous contraction and eso-
phageal pressurization and type III characterized by spastic contrac-
tions. Diﬀerent achalasia types show diﬀerences in the number of in-
ﬁltrating immune cells as well as the number of ganglions. It is as yet
unclear whether these subtypes are diﬀerent disease entities, or whe-
ther they are progressive stages of disease, but it has been proposed that
while type III is caused by a diﬀerent etiology, type II is an early form of
achalasia showing active inﬂammatory response against neurons and
type I represents a late form of achalasia where the loss of immune-
provoking ganglions results in loss of inﬂammation [37]. However,
histological analysis of the full-layer mucosa in early and advanced
achalasia showed that inﬂammation was present in early achalasia, but
histological esophagitis with ﬁndings of increased inﬂammatory cell
inﬁltration and dilated intercellular spaces were also observed in pa-
tients with late achalasia [38]. Furthermore, in patients with end-stage
achalasia, the squamous mucosa is consistently altered compared with
control specimens and closely resembles that seen in GERD with
Table 1
Diﬀerent cell types present in esophageal lining of the esophagus in health and diseases.
Heath/disease Cell types Disease manifestation
Healthy mucosa Squamous epithelial cells –
GERD Squamous epithelial cells Immune inﬁltrate; barrier defect
BE Mucinous columnar epithelial cells; enterocytes; Paneth cells; endocrine cells; cells
with combined gastric/intestinal or intestinal/squamous cell features
Immune inﬁltrate; spatial mislocalisation of intestinal barrier cells
Achalasia Squamous epithelial cells Immune inﬁltrate
EAC Derives from glandular cells near the stomach Gland-forming tumor with variable grade of diﬀerentiation (as deﬁned by
gland formation or mucinous diﬀerentiation)
ESCC Derives from squamous epithelial cells Squamous cell hyperproliferation with variable degree of diﬀerentiation
(as deﬁned by keratinization)
GERD: gastro-esophageal reﬂux disease, BE: Barret's esophagus, EAC: esophageal adenocarcinoma, ESCC: esophageal squamous cell carcinoma.
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diﬀerent grades of esophagitis [39]. Thus, chronic esophagitis is present
in achalasia patients, and as this is the main risk factor for ESCC de-
velopment, it may also contribute to the increased risk of ESCC in pa-
tients with achalasia [40]. However, as the diagnostic technique to
distinguish diﬀerent achalasia subtypes (high-resolution esophageal
pressure topography) is relatively novel [41], it is as yet unclear whe-
ther these carry diﬀerent risk of cancer development.
The occurrence of chronic esophageal inﬂammation in achalasia
patients can be partially explained by the LES-lowering therapy, which
may enhance gastro-esophageal reﬂux and predispose to BE develop-
ment. Indeed, GERD was diagnosed in up to 31.5% of achalasia patients
following myotomy and in up to 33% following pneumatic dilatation
[3,42]. BE develops in 8.4% of achalasia patients, while post-treatment
LES pressures were lower in patients with BE than in those without
[16]. Besides this systematic study, only a limited number of patients
have been described with a combination of achalasia and BE. This in-
cludes one patient who developed BE after pneumatic dilatation [43],
31 patients after surgical myotomy [33,43,44] and interestingly, eight
patients who were diagnosed with BE without being treated for their
achalasia [33,43,45]. Several hypotheses might explain this phenom-
enon, the ﬁrst being that the development of BE had occurred before
the onset of achalasia [46]. Secondly, a combination of transient LES
relaxations (TLESRs) and impaired esophageal clearance may co-occur
in achalasia patients thereby causing both diseases independently [47].
The third explanation is that the esophagitis in untreated achalasia
patients can be the consequence of fermentation and bacterial over-
growth through food stasis, especially when prominent dilatation of the
organ is seen (see below) [45]. Smart et al. [48] showed a low pH in the
esophagus of untreated patients without episodes of gastroesophageal
reﬂux; in addition, increased lactic acid and a lower esophageal pH
were present in patients with achalasia who had retained food, as
compared with those who did not. As stasis of food is common in
achalasia patients, even after dilatation treatment, it is diﬃcult to
distinguish between inﬂammation caused by acid reﬂux or food stasis.
These various possibilities are probably not exclusive of each other; it is
more likely that diﬀerent mechanisms operate in diﬀerent patients
[46,49]. Hence, these ﬁndings indicate that there is a direct patholo-
gical connection between achalasia and the development of Barrett's
segment. Chronic inﬂammation might be a link between these condi-
tions and their progression to cancer and it seems reasonable to assume
that the esophageal epithelium may be aﬀected by similar processes
during progression from GERD to BE and EAC and from achalasia to BE
and EAC or to ESCC.
3. Genetic alterations and molecular pathways involved in cancer
development in BE
While inﬂammatory processes are thought to contribute to carci-
nogenesis through the induction of DNA damage and growth ad-
vantage-conferring mutations, the molecular and genetic relationship
between EAC, ESCC, and achalasia as their precursor lesion, is poorly
understood. However, in order to identify possible therapeutic targets
for prevention and treatment of esophageal carcinoma, the molecular
pathways involved in the malignant progression from BE to EAC have
received vast attention [6]. Improvements in high-throughput genomic
technologies have led to a better understanding of the molecular basis
underlying the development of EAC and ESCC [50].
Analysis of gene mutations revealed that in EAC, 26 genes are fre-
quently and signiﬁcantly mutated. Among these genes are tumor sup-
pressors such as TP53 (72% of cases) and p16/CDKN2A (12% of cases)
as well as bacterial recognition receptor TLR4 mutations (6% of cases)
[51]. Interestingly, BE tissue appears to be highly mutated even prior to
the occurrence of dysplasia, with a mutation rate superior to many
other tumors at an advanced stage of development (6.76 mutations/
Mb) [52]. Thus, an accumulation of mutations appears to underlie the
BE-to-EAC sequence, which is already initiated at early BE stages. This
is seen for instance for TP53 mutations, which are scarce in BE, but
accumulate in EAC [53]. However, while a shared mutational context
suggests that the same mutational trigger underlies both BE and EAC, it
has also been shown that the mutations in BE are clonal, and the spe-
ciﬁc mutations observed in diﬀerent clones do not overlap greatly with
those found in EAC (for example, mutation of EYS, ARID1A, and ABCB1
genes was only shared in 28% of paired Barrett's and EAC samples)
[52]. Furthermore, while TP53 and P16 mutations are homogeneously
present within EACs, and appear to represent early events during car-
cinogenesis, clonality within EAC also exists, with loss of heterozygosity
of SMAD4 and APC not evenly distributed within the tumor [54].
Longitudinal genetic analysis of BE patients suggests that the number
and diversity of clones within BE segments changes little over time
[55], however, patients who progress to EAC during their lifetimes
(< 5%) develop signs of chromosome instability with gene losses and
gains, genomic heterogeneity, selection of somatic chromosome ab-
normalities and catastrophic genome doublings [56]. Esophageal
cancer development is also associated with a clear increase in copy
number alterations (CNAs), which are much less frequent in BE. Some
of these molecular abnormalities can be used to predict the neoplastic
progression risk of BE [57]. For instance, high clonal diversity was
associated with increased progression risk of BE [55].
In addition to gene mutations, altered gene transcription patterns
are observed in BE and EAC. Based on this pattern, prediction models
for progression have been developed with a 90-gene signature showing
promise as a biomarker for low grade dysplasia in BE [58]. Within this
signature, one third of genes was regulated by the proto-oncogene c-
MYC, with other candidates HNF1-α, SP-1, NF-Y, E2F1, TP53, ESR1 and
HIF1A following suit [58]. A recent review and meta-analysis con-
ﬁrmed the use of p53 immunohistochemical staining to improve risk
stratiﬁcation in BE surveillance [59].
3.1. Markers for progression of achalasia to cancer
Interestingly, esophagectomy specimens from achalasia patients
also display a heightened frequency of p53 immunoreactivity, in-
dicative of early changes related to ESCC risk [60]. Aberrant expression
of the p53 protein correlated with grade of inﬂammation in idiopathic
achalasia [61], and increased with progressive grades of dysplasia. A
recent study further showed that patients with achalasia and retention
esophagitis have higher positive rates of p53 and p16 expression (a key
regulator at the G1-S checkpoint in the cell cycle often deregulated in
cancers) than those from achalasia patients without retention esopha-
gitis and control groups [62]. These data suggest that achalasia-asso-
ciated chronic inﬂammation may mediate clonal evolution by gen-
erating a mutagenic pressure or providing a selective advantage to
those clones able to survive an inﬂammatory insult [63]. However,
aside from the above mentioned TP53 mutations, the mutation burden
in the mucosa of patients with achalasia is relatively uncharacterized
and the exact genetic evolution from achalasia to esophageal squamous
dysplasia and ESCC remains unknown. ESCC itself is characterized by
aneuploidy of chromosomes 7, 11, and 17 as well as TP53 gene deletion
[64]. Aneuploidy was also reported to be present in achalasia and
chagasic megaesophagus patients, with chromosome 7 monosomy or
trisomy and chromosome 17 monosomy or trisomy being the most
frequently occurring aneuploidies [64], suggestive of an achalasia-to-
ESCC carcinogenic sequence. Mutation of the PIK3CA gene was re-
ported to be associated with Chagas disease and ESCC, but there is no
evidence regarding its association with idiopathic achalasia [65].
As for EAC and BE, clonal expansion of ESCC and its premalignant
lesion esophageal squamous dysplasia are implicated by their highly
heterogeneous and polyclonal nature [66]. Dysplasia is heavily mutated
and harbors most of the driver events reported in ESCC, with TP53
mutations a prerequisite for progression to ESCC. However, unlike BE
to EAC progression, copy number alterations are already common in
dysplastic stages and persist during the ESCC progression. Whether
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these copy number alterations are already present at achalasia stages
remains unanswered.
Despite the presence of common denominators, including the
aforementioned TP53 point mutations, studies have indicated that
ESCC is genetically more similar to other squamous cancers, such as
head and neck, than to EAC [51,67]. Risk factors for ESCC include to-
bacco and alcohol consumption and this tumor is more common in the
upper and mid-esophagus, whereas the EAC predominates in the lower
esophagus and is associated with obesity and GERD [68]. A comparison
of copy number alterations as well as DNA methylation, mRNA and
microRNA expression patterns between 90 ESCCs and 72 EACs revealed
a clear separation between these types of esophageal cancer [69]. Al-
though both diseases share similarly high frequencies of overall and
clinically relevant genomic alterations, diﬀerent genetic mutations as-
sociated with speciﬁc cellular pathways, such as cell cycle, apoptosis,
DNA repair mechanisms, growth factor receptors, have been identiﬁed
in esophageal squamous cell cancers (see Tables 2, 3) [67]. When
achalasia progresses to EAC, the oncogenic events are likely to be dif-
ferent compared to the progression to ESCC. Again, the mutational
sequence from achalasia to BE remains unknown, and it would be of
interest to compare mutational burden in achalasia-associated EAC to
EAC that is not associated with achalasia.
3.2. Other molecular changes in achalasia patients
Except for investigation of the role of p53 and aneuploidy as pre-
dictive markers of neoplastic transformation, temporal information on
the molecular pathways involved in malignant transformation of
achalasia is limited. However, some studies have investigated the mo-
lecular events taking place during the presentation of achalasia itself.
A recent study found elevated miR-130a expression levels in eso-
phageal mucosa specimens of achalasia patients [70]. miR-130 serves
an important role in multiple types of tumors by targeting important
phospho-protein modulators of cell survival and migration signaling
[71]. Furthermore, functional classiﬁcation of whole transcriptome
analysis of achalasia esophageal biopsies revealed a signiﬁcant over-
representation of phosphorylation processes, intracellular signaling,
cell communication, and development/diﬀerentiation processes, in-
cluding cell death [72]. The major expression alterations contributing
to this proﬁle in achalasia patients were a downregulation of CYR61,
CTGF, c-KIT, DUSP5, EGR1 and an upregulation of AKAP6 and INPP4B.
One study investigating the onset and development of achalasia, al-
though not its neoplastic transformation, revealed 1728 diﬀerentially
expressed genes in achalasia mucosa [73]. These fell into 5 major
classes of pathways: cell migration, cell signaling, neuron signaling,
immune response, and actin stress ﬁber formation and regulation,
suggesting that achalasia at early stages shows potential oncogenic al-
terations. Interestingly, upstream regulator analysis of these expression
patterns revealed TLR4 and IL18 to be the most signiﬁcant and acti-
vated regulators.
TLR4 is a transmembrane protein receptor that recognizes pa-
thogen-associated molecular patterns released by viruses and bacteria
[74]. The relationship between TLR4 signaling and tumorigenesis is
complex with evidence showing that TLR4 signaling can enhance or
suppress cancer development, depending on the model system [75].
TLR4 expression increases from normal esophageal epithelium to low-
grade dysplasia – high-grade dysplasia -EAC and is associated with
advanced stage and poor prognosis in EAC [76]. However, it was later
shown that TLR pathway genes are frequently mutated in EAC and that
these mutations decrease responsiveness to bacterial ligands [75]. TLR4
expression is also increased in ESSC [77], and correlates to tumor stage,
diﬀerentiation grade (good, moderate and poor) and risk of metastasis
[78], but mutations in TLR4 gene are less frequent [79]. These data
suggest a diﬀerence in how the bacterial composition in achalasia and
Table 2
Dysregulated genes observed in Barrett's esophagus (BE), esophageal adeno-
carcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). When
known, frequencies are reported (adapted from: [54, 71–74]).
Gene BE (%) EAC (%) ESCC (%)
Receptor tyrosine kinases
ERBB2 01–13 32 3
EGFR 0–4 15 19
KRAS present, frequency not reported 14 7
PIK3CA 0–4 3 13
Cell cycle regulators
CDKN2A 30–42 76 76
CCND1 present, frequency not reported 15 57
CCNE1 present, frequency not reported 14 4
RB 0–8 0 9
Proliferation and diﬀerentiation
MYC present, frequency not reported 32 23
SMAD4 0 24 8
GATA4 present, frequency not reported 19 1
GATA6 present, frequency not reported 21 3
TP63 OR SOX2 11 48
Chromatin remodeling
KMT2D 4–13 1 14
Cell death
TP53 2.5–72 75 69
Cell adhesion, migration, cytoskeleton organization
TTN 55 34
MUC16 31 14
SYNE1 3–4 30 11
Other mutated genes
TLR4 13 5 1
LRP1B 0–4 25 11
Table 3
Genes associated with achalasia. Adapted from [74–79]. When known, fre-
quencies of mutation in esophageal cancer are reported (adapted from: [54,
71–74]).
Gene Role in achalasia EAC (%) ESCC (%)
Cell death
TP53 Increased expression in achalasia 75 69
Cell cycle regulators
CDKN2A Increased expression in achalasia 76 76
Immunology
HLA Variants confer susceptibility to idiopathic
achalasia
0.62–2.17
Nos1 Mouse knockout model for achalasia 3
LTA/TNFα Likely involved in onset of disease
IL10 Likely involved in onset of disease 0
IL23 Likely involved in onset of disease
DNA methylation and repair
Rassf1a Mouse knockout model for achalasia
Receptor tyrosine kinase signaling
Kit Mouse knockout model for achalasia 1 2
RET Likely involved in onset of disease 3
Spry2 Mouse knockout model for achalasia
Neurological processes
GDNF Likely involved in onset of disease
VIPR1 Likely involved in onset of disease
MYO5B Likely involved in onset of disease 2
ADRB2 Likely involved in onset of disease
Other
AAAS Likely involved in onset of disease 0
GUCY1A1 Associated with moyamoya disease 6 with
achalasia
2
GMPPA Associated with alacrima, achalasia and
mental retardation syndrome
EAC: esophageal adenocarcinoma.
ESCC: esophageal squamous cell carcinoma.
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BE contribute to the formation of ESSC and AEC, respectively.
4. The possible role of the microbiome in BE- and achalasia-
associated cancer
One of the contributing factors to induce and maintain chronic in-
ﬂammation is the microbiota. The classic germ theory of disease de-
scribed an infectious disease as the direct result of a single pathogen
which can become virulent and predispose the host to inﬂammation
and disease, for example, Helicobacter pylori is a causative agent of
gastric ulcers and gastric cancer and C. diﬃcile, in causing diarrhea and
colitis [80]. Nowadays, dysbiosis within the microbial community,
deﬁned as any change to the composition of resident commensal
communities relative to the community found in healthy individuals is
considered a potential cause of disease. Three types of dysbiosis have
been described: 1) loss of beneﬁcial microbial organisms, 2) expansion
of overall pathobionts and 3) loss of overall microbial diversity [81].
Our body hosts 1013 bacteria, most of which reside in the intestine,
requiring a complex interplay between the microbiota and mucosal
epithelial cells, innate and adaptive immune responses [82]. Several
diseases have now been associated with alterations in the microbiome,
including gastrointestinal cancers [83]. Thus, it is tempting to speculate
on a possible role of single microbial pathogens or dysbiosis in the
development and progression of BE or esophageal achalasia toward
cancer.
4.1. Microbiome in BE
Although the esophagus and stomach previously seemed unin-
habitable, new molecular techniques allowing the detection of micro-
bial DNA now indicate that a range of microbes is present in these
organs. Sequencing of the universal bacterial 16S ribosomal RNA gene
showed that Gram-positive bacteria are typical of the healthy eso-
phagus [84]. Around 100 unique taxa are present in the esophagus,
consisting of 6 major phyla: Firmicutes, Bacteroidetes, Actinobacteria,
Proteobacteria, Fusobacteria, and TM7, with 39% of isolates belonging
to the Streptococcus genus, followed by Prevotella (17%) and Veillonella
(14%). The healthy esophageal microbiome has been recently clustered
into 3 functionally distinctive community types (esotypes) deﬁned by
diversity and composition [85]. The ﬁrst esotype is characterized by an
abundance of Streptococcus and Prevotella as well as increased levels of
Haemophilus (Haemophilus parainﬂuenzae) and Rothia (Rothia mucilagi-
nosa). Dominance of Streptococcus is typical for the second esoptype,
whereas dominance of Prevotella and Veillonella is seen in the third
group. Thus, the esophageal microbiota is a relatively stable and unique
community and not merely composed of organisms in transit [86].
Yang et al. compared the microbiota of GERD and BE patients with
healthy subjects and showed that the esophageal microbial community
in GERD patients was associated with by a greater number of obligate
anaerobes, such as Bacteroidetes phylotypes (e.g., 13% Prevotella) and
Gram-negative Proteobacteria (e.g., 6% Haemophilus, 5% Neisseria).
[87]. Generally, BE is also characterized by an increased relative
abundance of Gram-negative bacteria, including Fusobacterium, Neis-
seria, Campylobacter, Bacteroides, Proteobacteria, and Veillonella taxa,
and decreased levels of Gram-positive Streptococcus. Furthermore, the
bacterial load in BE patients appears to be increased compared to non-
BE patients [88]. Deshpande et al. have also described relevant mi-
crobial signatures and metabolic pathways associated with GERD and
BE [85]. An enrichment of bacterial superpathway of hexitol degrada-
tion, microbial lactic acid production (homolactic fermentation) and an
increase in heme biosynthesis from glycine or uroporphyrinogen was
found in GERD, whereas heterolactic fermentation increased in BE.
Fig. 2. In patients with achalasia, abnormal lower esophageal sphincter (LES) pressure leads to food accumulation and bacterial overgrowth in the dilated esophagus.
Subsequently, DNA damage can occur through inﬂammation induced by N-nitrosocompounds (NOC), lipopolysaccharide (LPS) and lactic acid produced by bacteria,
by lactic acid formed during the digestion of food, and by reactive oxygen species (ROS) produced by involved immune cells and during metabolism of bacterial
heme. LPS can also contribute to LES relaxation and occurrence of BE. Altogether, it suggests possible role of microbiota in achalasia-associated cancer development.
TLR: toll-like receptor.
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Thus, GERD and BE are associated with distinct alterations in the eso-
phageal microbial composition and their associated metabolic changes.
4.2. A role for the microbiome in achalasia and progression to EAC/ESSC?
To the best of our knowledge, the microbiome of patients with
idiopathic achalasia is not characterized. However, this disease induces
progressive dilatation of the organ, eventually causing megaesophagus,
a clinical presentation which is also typical for patients with pseu-
doachalasia [89] and Chagas disease, a parasitic disease caused by
Trypanosoma cruzi [90].
Culture-based studies have shown that the chagasic megaesophagus
microbiome is dominated by anaerobic Gram-negative Veillonella and
aerobic Gram-positive Streptococcus [91] and that bacterial load cor-
relates with the degree of esophageal dilation. Our own studies suggest
that achalasia is often accompanied by fungal growth (unpublished
data) and it is to be expected that food stasis will induce local altera-
tions of both the micro- and mycobiome in these patients.
Several theories have been discussed to explain how changes in
microbiome could predispose to BE and EAC, and similar mechanisms
of microbiota-associated cancer development could apply to achalasia-
related cancer (Fig. 2).
First, abnormal LES function is incompletely understood, and might
actually stem from esophageal dysbiosis. As mentioned above, it sug-
gested that a Gram-negative bacteria-dominated esotype may play a
causative role in GERD [87]. In animal studies, lipopolysaccharide
(LPS), a product of Gram-negative bacteria, has been shown to relax the
LES and delay gastric emptying [92]. Alternatively, this esotype might
be secondary to the changes caused by gastric reﬂux [93]. Motility
disturbances in BE patients such as weak LES pressure and poor con-
tractility [94] may predispose to bacterial overgrowth in the distal
esophagus or modiﬁcation of the esophageal microbiome by selecting
against acid-sensitive bacteria in the esophagus [93]. This can cause the
further disturbance of the LES and increase of reﬂux.
The second possibility is that Gram-negative bacteria can promote
chronic low-grade tissue inﬂammation, thereby contributing to the
development of metaplasia and inﬂammation-induced carcinogenesis
[95]. The esophageal mucosa faces a quite aggressive environment with
permanent mechanical and chemical irritation: wear and tear, heating,
or cooling after swallowing food boluses and contact with gastric and
gastroduodenal acidic contents during reﬂux episodes. In inﬂammatory
conditions such as GERD and achalasia [20], impairment of the eso-
phageal barrier may, in theory, lead to direct contact of mucosal im-
mune cells and microbiota. Thus, bacterial overgrowth and presence of
Gram-negative bacteria in achalasia patients may lead to higher bac-
terial antigen loading on antigen presenting innate immune cells and
subsequent triggering of adaptive immune responses conductive of
neoplastic transformation. Bacterial products may also directly activate
innate immune responses and promote tissue inﬂammation. For in-
stance, LPS detection by TLR4 leads to activation of the pro-in-
ﬂammatory transcription factor NF-κB, a signaling molecule that plays
a pivotal role in many tissue inﬂammatory responses and expression
levels of which are increased along the spectrum from BE to EAC [29].
In addition to general changes in the microbiome, particular species
have also been associated with esophageal pathology [86]. While early
culture-based studies of esophagectomy specimens from both EAC and
ESCC samples did not note any diﬀerence in organisms isolated in be-
nign versus malignant tissue [96], a more recent study using 16S se-
quencing found increased Treponema denticola and Streptococcus species
in esophageal cancer patients compared to controls [97]. These Strep-
tococcus strains were subsequently shown to induce pro-inﬂammatory
cytokine production in esophageal cancer cell lines. Blackett et al. de-
monstrated signiﬁcant enrichment of Campylobacter in GERD and BE,
but not EAC, as compared controls and demonstrated that cytokines
linked with carcinogenesis (eg IL-18) were increased in tissues colo-
nized by Campylobacter [98]. This notion is consistent with the ‘driver-
passenger’ theory, which states that carcinogenic bacteria may be dis-
placed or outcompeted by non-carcinogenic bacteria due to changes in
the local niche upon cellular transformation [99]. Another bacterial
driver of esophageal cancer might be Fusobacterium nucleatum, a bac-
terium shown to directly promote colorectal carcinogenesis through
activation of molecular pathways governing cell adhesion and migra-
tion (e.g. E-cadherin/b-catenin) [100], and the abundance of which has
also been noted in BE [87,93].
Lastly, the third link from bacteria to carcinogenesis is through their
metabolites (N-nitrosocompounds, lactic acid, heme). Gram-negative
bacteria can reduce dietary nitrates to nitrites, which in turn are pre-
cursors of the carcinogenic N-nitrosocompounds formed in the acidic
environment of the cardia and distal esophagus in reﬂux disease [101].
This hypothesis is supported by the fact that Macfarlane et al. identiﬁed
bacterial species that produce nitrosamines in patients with BE. The
presence of bacteria that promote nitrosamine production correlated
with consequent tissue metaplasia and dysplasia [102]. Patients with
megaesophagus also possess bacteria in the esophageal lumen with the
capacity to metabolize nitrates [91]. Thus, increased concentrations of
microbial metabolites within the esophagus and stasis of dietary car-
cinogens can be the reason for the increased prevalence of ESCC in
patients with achalasia and megaesophagus [103]. In addition, it is
shown that heme can damage colon epithelium and induce its hyper-
proliferation by causing oxidative stress; its production by bacteria is
also increased in GERD [85,104].
Thus, while data characterizing the microbiome of achalasia pa-
tients is lacking, it is likely that some of the bacteria related to cancer
development may also contribute to cancer risk in this group of pa-
tients. For ESCC, the microbiome is also relatively poorly characterized
[105]. Nevertheless, Yu et al. observed a negative correlation between
esophageal microbial richness and esophageal squamous dysplasia (the
precursor lesion of esophageal squamous cell carcinoma) [106] and
other studies showed that Clostridiale, Erysipelotrichales and F. nucleatum
are enriched in patients with ESCC [107,108]. In addition, severity and
prognosis of disease correlate with the presence of Porphyromonas gin-
givalis [109]. Thus, an increased bacterial load, presence of antigens,
persistent mechanical and chemical irritation of epithelium and direct
and indirect mediation of bacterial-induced inﬂammation may all
contribute to carcinogenesis. Besides a role in neoplastic transforma-
tion, the microbiome can also contribute to some of the comorbidities
of megaesophagus, such as recurrent aspiration pneumonia and chronic
pulmonary infections, as well as infectious complications related to
esophageal perforation during surgical or endoscopic procedures [110].
5. Concluding remarks
Achalasia is a rare esophageal disease that increases the risk of
development of two types of cancer. Achalasia can progress to ESCC or
BE and then to EAC. Both precursor lesions achalasia and BE are as-
sociated with chronic inﬂammation that can contribute to neoplastic
transformation, however, BE is relatively well characterized in terms of
genetic alterations, molecular pathways and microbiota changes.
Analysis of genomic and transcriptomic changes in the esophageal
mucosa of achalasia patients that do and do not progress to esophageal
cancer might reveal novel targets for therapeutic approach and pre-
dictive markers. The studying of evolutionary dynamics of achalasia
might be important both for understanding the fundamental process of
neoplastic progression and for the clinical management of the disease.
It might help to determine high risk patients for regular surveillance
which is under discussion for achalasia patients and the spatiotemporal
dynamics of clonal evolution occurring in achalasia might be poten-
tially useful for optimization of endoscopic surveillance intervals in this
group. BE is characterized by distinct alterations in the esophageal
microbial content. Microbiota might play an even more important role
in the transformation of epithelium in achalasia patients due to con-
tinuing food stack and bacteria overgrowth. It might contribute to
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abnormal LES functioning, to the maintenance of chronic inﬂammatory
status and inﬂuence esophageal mucosa with carcinogenic by-products.
Moreover, the diﬀerence in responsiveness to bacterial ligands via TLR4
could be determinative to what type of cancer achalasia will progress.
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